Genexine Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Genexine heeft een totaal eigen vermogen van ₩288.1B en een totale schuld van ₩68.5B, wat de schuld-eigenvermogensverhouding op 23.8% brengt. De totale activa en totale passiva bedragen respectievelijk ₩365.4B en ₩77.3B.

Belangrijke informatie

23.8%

Verhouding schuld/eigen vermogen

₩68.53b

Schuld

Rente dekkingsratio	n/a
Contant	₩52.50b
Aandelen	₩288.07b
Totaal verplichtingen	₩77.32b
Totaal activa	₩365.39b

Recente financiële gezondheidsupdates

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Jul 12

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Mar 14

Recent updates

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Jul 12

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Mar 14

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 19

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₩66.7B ) A095700 } overtreffen de korte termijn passiva ( ₩51.8B ).

Langlopende schulden: De kortetermijnactiva A095700 ( ₩66.7B ) overtreffen de langetermijnschulden ( ₩25.5B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 5.6% ) A095700 wordt als voldoende beschouwd.

Schuld verminderen: Er zijn onvoldoende gegevens om te bepalen of de schuld/eigen vermogen-ratio van A095700 de afgelopen 5 jaar is gedaald.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: A095700 heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: A095700 heeft minder dan een jaar aan kasmiddelen als de vrije kasstroom blijft dalen met historische percentages van 5.7 % per jaar.

Genexine Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Recent updates

New minor risk - Shareholder dilution

We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D

Full year 2023 earnings released: ₩1,652 loss per share (vs ₩1,715 loss in FY 2022)

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

New minor risk - Revenue size

New minor risk - Share price stability

Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority (BPOM)

Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study

Ajinomoto Co., Inc. (TSE:2802) agreed to acquire remaining 25% stake in Ajinomoto Genexine Co., Ltd from Genexine, Inc. (KOSDAQ:A095700) for KRW 19.3 billion.

Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for Its Promising DNA Vaccine for Advanced Cervical Cancer

Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

Genexine, Inc. has completed a Follow-on Equity Offering in the amount of KRW 82.044713 billion.

No independent directors

Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

First quarter 2021 earnings released: EPS ₩861 (vs ₩628 loss in 1Q 2020)

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Genexine, Inc., Annual General Meeting, Mar 29, 2021

New 90-day low: ₩94,300

Turret Capital Management Signs A Definitive License Agreement with Genexine, Inc

New 90-day low: ₩103,600

Genexine, Inc. and NeoimmuneTech, Inc. Releases Data for Their Phase 1B/2 Study of Gx-I7/Nt-I7 and Keytruda® in Patients with Triple-Negative Breast Cancer

New 90-day low: ₩104,000

New 90-day low: ₩109,500

Genexine, Inc. announced that it has received KRW 3.29761 billion in funding from Handok, Inc.

New 90-day high - ₩132,000

New 90-day high - ₩130,600

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven